Autonomix Medical, Inc. AMIX 深 滬
已收盤 12-19 16:00:00 美东时间
0.625
-0.006
-0.92%
華盛通- 最 高0.6435
- 今 開0.622
- 成交量 19.14万股
- 最 低 0.605
- 昨 收 0.6308
- 總市值 371.38万
- 52周最高 4.58
- 市盈率 靜 --
- 換手率 3.22%
- 52周最低 0.6013
- 委 比 -98.59%
- 總股本 594.20万
- 歷史最高 21.49
- 量 比 0.42
- 振 幅 6.10%
- 歷史最低 0.6013
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Autonomix Medical announces pricing of $5M private placement
Autonomix Medical (NASDAQ:AMIX) stated on Tuesday that it has entered into an agreement with a single institutional investor to purchase 4.5M shares of common stock and, together with unregistered Ser...
11-18 21:59
Autonomix Medical shares are trading higher after the company reported post-hoc subgroup analysis results from its first-in-human study showing potential quality-of-life improvements with its targeted ablation therapy.
Autonomix Medical shares are trading higher after the company reported post-hoc...
11-17 21:02
Autonomix Medical To Present At TCT 2025 Conference Showcasing Initial Results From Its First-in-Human Study On Transvascular Nerve-Targeted Therapy To Reduce Pancreatic Cancer Pain
Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will be featured in two podium
10-24 21:05
Autonomix Medical, Inc. Featured in Two Innovation in Interventional Cardiology Podium Presentations at the Transcatheter Cardiovascular Therapeutics® (TCT®) Annual Scientific Conference
Autonomix Medical, Inc. will present two podium sessions at TCT 2025 in San Francisco, showcasing positive results from their first-in-human proof-of-concept study on transvascular energy delivery to ablate problematic nerves, targeting pancreatic cancer pain. The presentations highlight innovative technology for nerve-targeted treatments and its potential in chronic disease management.
10-24 13:00
Autonomix Medical, Inc. to Highlight Innovative Nerve-Sensing and Ablation Platform at the 2025 Maxim Growth Summit
Autonomix Medical, Inc. will participate in the 2025 Maxim Growth Summit on October 22-23 in New York. The event will feature in-person meetings with investors and showcase the company's innovative neural sensing technology for treating nervous system diseases, initially targeting pain management in conditions like pancreatic cancer. Maxim Group, a full-service financial firm, is organizing the summit. For more details, visit www.maximgrp.com/202...
10-16 13:15
Autonomix Secures New U.S. Patent Titled, "Controlled And Precise Treatment Of Cardiac Tissues"
With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulationNewly issued patent strengthens the Company's strategic position in a
10-09 20:46
Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System
Autonomix Medical, Inc. launched a GLP preclinical study for its pancreatic cancer pain treatment system, a key step toward FDA regulatory approval. The company aims to submit an Investigational Device Exemption (IDE) application and, if approved, begin U.S. clinical trials in 2026. CEO Brad Hauser highlighted this as a significant milestone in the company's regulatory pathway.
09-29 13:15
Autonomix Medical, Inc. Announces Abstract Accepted for Podium Presentation at the 2025 CIRSE Annual Congress
<p>Autonomix Medical, Inc. will present findings from its first-in-human proof-of-concept study at the 2025 CIRSE Annual Congress in Barcelona. The podium presentation, titled "Pain mitigation in pancreatic adenocarcinoma: an analysis of neurolysis via transvascular radiofrequency (RF) ablation," will discuss how AI enhances interventional radiology. The session will take place on September 15, 2025. Autonomix is focused on advancing precision ne...
09-09 13:00
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment
Autonomix Medical, Inc. (NASDAQ: AMIX), a medical device company, announced the release of a Virtual Investor "What This Means" segment featuring Dr. Robert Schwartz, its Chief Medical Officer. Dr. Schwartz discussed the company's recent post hoc analysis of its proof-of-concept human clinical trial ("PoC 1"), which showed sustained pain reduction, improved quality of life, and 100% opioid-free outcomes. The segment highlights the company's innov...
09-04 13:00
Autonomix Medical Announces Extended Post Hoc Data From First-In-Human Study On Transvascular Nerve Ablation For Pancreatic Cancer Pain Relief
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain100%
09-03 20:41
